Boron Neutron Capture Therapy (BNCT) for Cutaneous Malignant Melanoma Using <sup>10</sup>B-p-Boronophenylalanine (BPA) with Special Reference to the Radiobiological Basis and Clinical Results

BNCT is a radiotherapeutic method for cancer treatment that uses tumor-targeting <sup>10</sup>B-compounds. BNCT for cutaneous melanoma using BPA, a phenylalanine derivative, was first initiated by Mishima et al. in 1987. This article reviews the radiobiological basis of melanoma control...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Hiroshi Fukuda
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	radiobiology BNCT BPA melanoma clinical outcome Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/f024098162034ed591db9662ac026369
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f024098162034ed591db9662ac026369
record_format	dspace
spelling	oai:doaj.org-article:f024098162034ed591db9662ac0263692021-11-25T17:08:29ZBoron Neutron Capture Therapy (BNCT) for Cutaneous Malignant Melanoma Using <sup>10</sup>B-p-Boronophenylalanine (BPA) with Special Reference to the Radiobiological Basis and Clinical Results10.3390/cells101128812073-4409https://doaj.org/article/f024098162034ed591db9662ac0263692021-10-01T00:00:00Zhttps://www.mdpi.com/2073-4409/10/11/2881https://doaj.org/toc/2073-4409BNCT is a radiotherapeutic method for cancer treatment that uses tumor-targeting <sup>10</sup>B-compounds. BNCT for cutaneous melanoma using BPA, a phenylalanine derivative, was first initiated by Mishima et al. in 1987. This article reviews the radiobiological basis of melanoma control and damage to normal tissues as well as the results of clinical studies. Experimental studies showed that the compound biological effectiveness (CBE) values of the <sup>10</sup>B (n, α)<sup>7</sup>Li reaction for melanoma control ranged from 2.5 to 3.3. The CBE values of the <sup>10</sup>B (n, α)<sup>7</sup>Li reaction for skin damage ranged from 2.4 to 3.7 with moist desquamation as the endpoint. The required single radiation dose for controlling human melanoma was estimated to be 25 Gy-Eq or more by analyzing the 50% tumor control dose data of conventional fractionated radiotherapy. From the literature, the maximum permissible dose to human skin by single irradiation was estimated to be 18 Gy-Eq. With respect to the pharmacokinetics of BPA in patients with melanoma treated with 85–350 mg/kg BPA, the melanoma-to-blood ratio ranged from 2.1–3.8 and the skin-to-blood ratio was 1.31 ± 0.22. Good local tumor control and long-term survival of the patients were achieved in two clinical trials of BNCT conducted in Japan.Hiroshi FukudaMDPI AGarticleradiobiologyBNCTBPAmelanomaclinical outcomeBiology (General)QH301-705.5ENCells, Vol 10, Iss 2881, p 2881 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	radiobiology BNCT BPA melanoma clinical outcome Biology (General) QH301-705.5
spellingShingle	radiobiology BNCT BPA melanoma clinical outcome Biology (General) QH301-705.5 Hiroshi Fukuda Boron Neutron Capture Therapy (BNCT) for Cutaneous Malignant Melanoma Using <sup>10</sup>B-p-Boronophenylalanine (BPA) with Special Reference to the Radiobiological Basis and Clinical Results
description	BNCT is a radiotherapeutic method for cancer treatment that uses tumor-targeting <sup>10</sup>B-compounds. BNCT for cutaneous melanoma using BPA, a phenylalanine derivative, was first initiated by Mishima et al. in 1987. This article reviews the radiobiological basis of melanoma control and damage to normal tissues as well as the results of clinical studies. Experimental studies showed that the compound biological effectiveness (CBE) values of the <sup>10</sup>B (n, α)<sup>7</sup>Li reaction for melanoma control ranged from 2.5 to 3.3. The CBE values of the <sup>10</sup>B (n, α)<sup>7</sup>Li reaction for skin damage ranged from 2.4 to 3.7 with moist desquamation as the endpoint. The required single radiation dose for controlling human melanoma was estimated to be 25 Gy-Eq or more by analyzing the 50% tumor control dose data of conventional fractionated radiotherapy. From the literature, the maximum permissible dose to human skin by single irradiation was estimated to be 18 Gy-Eq. With respect to the pharmacokinetics of BPA in patients with melanoma treated with 85–350 mg/kg BPA, the melanoma-to-blood ratio ranged from 2.1–3.8 and the skin-to-blood ratio was 1.31 ± 0.22. Good local tumor control and long-term survival of the patients were achieved in two clinical trials of BNCT conducted in Japan.
format	article
author	Hiroshi Fukuda
author_facet	Hiroshi Fukuda
author_sort	Hiroshi Fukuda
title	Boron Neutron Capture Therapy (BNCT) for Cutaneous Malignant Melanoma Using <sup>10</sup>B-p-Boronophenylalanine (BPA) with Special Reference to the Radiobiological Basis and Clinical Results
title_short	Boron Neutron Capture Therapy (BNCT) for Cutaneous Malignant Melanoma Using <sup>10</sup>B-p-Boronophenylalanine (BPA) with Special Reference to the Radiobiological Basis and Clinical Results
title_full	Boron Neutron Capture Therapy (BNCT) for Cutaneous Malignant Melanoma Using <sup>10</sup>B-p-Boronophenylalanine (BPA) with Special Reference to the Radiobiological Basis and Clinical Results
title_fullStr	Boron Neutron Capture Therapy (BNCT) for Cutaneous Malignant Melanoma Using <sup>10</sup>B-p-Boronophenylalanine (BPA) with Special Reference to the Radiobiological Basis and Clinical Results
title_full_unstemmed	Boron Neutron Capture Therapy (BNCT) for Cutaneous Malignant Melanoma Using <sup>10</sup>B-p-Boronophenylalanine (BPA) with Special Reference to the Radiobiological Basis and Clinical Results
title_sort	boron neutron capture therapy (bnct) for cutaneous malignant melanoma using <sup>10</sup>b-p-boronophenylalanine (bpa) with special reference to the radiobiological basis and clinical results
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/f024098162034ed591db9662ac026369
work_keys_str_mv	AT hiroshifukuda boronneutroncapturetherapybnctforcutaneousmalignantmelanomausingsup10supbpboronophenylalaninebpawithspecialreferencetotheradiobiologicalbasisandclinicalresults
_version_	1718412749949632512

Boron Neutron Capture Therapy (BNCT) for Cutaneous Malignant Melanoma Using <sup>10</sup>B-p-Boronophenylalanine (BPA) with Special Reference to the Radiobiological Basis and Clinical Results

Ejemplares similares